Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sophiris Bio Inc SPHS

Healthcare Biotechnology
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.


EXPM:SPHS - Post by User

Sophiris Bio Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by Chrysler_Kidon Jun 14, 2013 11:12am
194 Views
Post# 21525212

1 Year Target Est.

1 Year Target Est.

yahoo! finance has a 1 year target estimate for sophiris bio at $10.00...I wonder what their basing this estimate on...any thoughts people?..https://ca.finance.yahoo.com/q;_ylt=Ar7Eo5HHwVuj4YbE5pX7.64G6ppG;_ylu=X3oDMTEzYWswdjZoBHBvcwMxMgRzZWMDeWZpUXVvdGVzVGFibGUEc2xrA3Noc3Rv?s=SHS.TO.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities